Revolution Medicines (NASDAQ:RVMD) Insider Sells $16,736,000.00 in Stock

Key Points

• Insider Mark Goldsmith sold 80,000 shares of Revolution Medicines for approximately $16.7 million, reducing his ownership by 23.03% to 267,330 shares.
• RVMD traded near its 52-week high at $211.40, while the company reported a quarterly loss of $3.06 per share—worse than analysts’ expected loss of $2.04 per share.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating, although the average price target of $167.89 is below the current share price; institutional investors own 94.34% of the stock.

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark Goldsmith sold 80,000 shares of Revolution Medicines stock in a transaction on Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the sale, the insider owned 267,330 shares in the company, valued at $55,925,436. This represents a 23.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Revolution Medicines Stock Performance

RVMD traded down $0.18 during trading on Tuesday, hitting $211.40. 1,377,215 shares of the stock were exchanged, compared to its average volume of 3,018,515. The firm has a market capitalization of $45.31 billion, a P/E ratio of -23.97 and a beta of 1.39. Revolution Medicines, Inc. has a 1-year low of $35.62 and a 1-year high of $220.34. The stock has a fifty day moving average price of $189.02 and a two-hundred day moving average price of $145.65. The company has a quick ratio of 11.38, a current ratio of 11.38 and a debt-to-equity ratio of 0.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share for the quarter, missing analysts' consensus estimates of ($2.04) by ($1.02). During the same quarter in the prior year, the firm posted ($1.31) earnings per share. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Hedge Funds Weigh In On Revolution Medicines

Institutional investors have recently bought and sold shares of the company. Nextech Invest Ltd. boosted its holdings in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after acquiring an additional 1,304,347 shares in the last quarter. Millennium Management LLC raised its holdings in Revolution Medicines by 681.8% during the first quarter. Millennium Management LLC now owns 156,353 shares of the company's stock worth $5,529,000 after purchasing an additional 136,353 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Revolution Medicines by 14.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 300,196 shares of the company's stock valued at $10,615,000 after purchasing an additional 37,345 shares during the period. Invesco Ltd. boosted its holdings in Revolution Medicines by 19.3% in the 2nd quarter. Invesco Ltd. now owns 227,019 shares of the company's stock valued at $8,352,000 after purchasing an additional 36,760 shares in the last quarter. Finally, Jump Financial LLC boosted its holdings in Revolution Medicines by 87.9% in the 2nd quarter. Jump Financial LLC now owns 15,258 shares of the company's stock valued at $561,000 after purchasing an additional 7,137 shares in the last quarter. 94.34% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

RVMD has been the topic of several research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Revolution Medicines in a research report on Friday, July 17th. Piper Sandler increased their target price on shares of Revolution Medicines to $172.00 and gave the stock an "overweight" rating in a research note on Thursday, May 7th. Royal Bank Of Canada raised their price target on Revolution Medicines from $182.00 to $203.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. Needham & Company LLC boosted their price target on Revolution Medicines from $236.00 to $240.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. Finally, Truist Financial upped their price objective on Revolution Medicines from $210.00 to $231.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $167.89.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source